A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Author:

Cabanillas Maria E.1,Schlumberger Martin2,Jarzab Barbara3,Martins Renato G.4,Pacini Furio5,Robinson Bruce6,McCaffrey Judith C.7,Shah Manisha H.8,Bodenner Donald L.9,Topliss Duncan10,Andresen Corina11,O'Brien James P.11,Ren Min11,Funahashi Yasuhiro12,Allison Roger13,Elisei Rossella14,Newbold Kate15,Licitra Lisa F.16,Sherman Steven I.1,Ball Douglas W.17

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal DisordersDivision of Internal MedicineThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Department of Nuclear Medicine and Endocrine OncologyGustave Roussy Institute and Université Paris‐SudVillejuif France

3. Department of Nuclear Medicine and Endocrine OncologyMaria Sklodowska‐Curie Memorial Cancer Center and Institute of OncologyGliwice Branch, Gliwice PolandWybrzeze Armii Krajowej 15, 44‐101 Gliwice Poland

4. Department of Thoracic/Head and Neck Oncology, School of MedicineUniversity of WashingtonSeattle Washington

5. Section of EndocrinologyUniversity of SienaSiena Italy

6. Faculty of Medicine, Cancer Genetics UnitKolling Institute, Royal North Shore Hospital, University of SydneyNew South Wales Australia

7. H. Lee Moffitt Cancer Center and Research InstituteTampa Florida

8. Ohio State University Comprehensive Cancer CenterColumbus Ohio

9. Department of GeriatricsUniversity of Arkansas for Medical sciencesLittle Rock Arkansas

10. Department of Endocrinology and DiabetesThe Alfred HospitalMelbourne Victoria Australia

11. Eisai IncWoodcliff Lake New Jersey

12. Eisai IncAndover Massachusetts

13. Cancer Care ServicesThe Royal Brisbane and Women's HospitalHerston Queensland Australia

14. Department of EndocrinologyUniversity of PisaPisa Italy

15. Department of OncologyRoyal Marsden HospitalLondon United Kingdom

16. Foundation for Cancer Research and TreatmentNational Tumor InstituteMilan Italy

17. The Johns Hopkins University School of MedicineBaltimore Maryland

Funder

Supported by Eisai Inc

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3